TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Reduction in free androgen index (FAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction in serum concentration of LH-stimulated testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: push-out bond strength of white MTA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: grade 2-3 anemia
Endpoint domain: Adverse events/effects
Primary endpoint: Delivery at <37 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: excessive flatus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: breath excretion of hydrogen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Physical recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective global function scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Caries-inhibiting effect on enamel and dentine lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Penile rigidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of AKI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: combined hospital stay for heart failure and death from any cause
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Ability to link thoughts and feelings
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Peak oxygen uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Absolute claudication time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric motility improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: cardiac magnetic resonance-assessed infarct size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: myocardial salvage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: median creatine kinase areas under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in peripheral CD20+ lymphocyte numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: COPD diagnostic yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of responders to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in ESR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in fibrinogen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in insulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Immediate AF recurrence prevalence
Endpoint domain: Mortality/survival
Primary endpoint: AF-free rate at 14 months post-ablation
Endpoint domain: Mortality/survival
Primary endpoint: mechanical-touch threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change from baseline in morning FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: As-needed beta-agonist use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Morning peak expiratory flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pain-free at 2 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in photophobia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in phonophobia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predict mortality
Endpoint domain: Mortality/survival
Primary endpoint: bleeding days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: menstrual recovery on time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: nutritional knowledge
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Death or major disability at 90 days
Endpoint domain: Mortality/survival
Primary endpoint: Major disability at 90 days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Total cartilage volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: apical seal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: SPI-24 values on Evaluation Day 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rates of nausea
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of dizziness
Endpoint domain: Adverse events/effects
Primary endpoint: mouth opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: new silent infarct or stroke
Endpoint domain: Mortality/survival
Primary endpoint: mean SOFA score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: morphine use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity of CuZnSOD in platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of CMV disease
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of superinfections
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative inflammation reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CV and renal safety and efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CV and renal safety and efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Total score of the Tinetti test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hearing loss
Endpoint domain: Adverse events/effects
Primary endpoint: Glomerular filtration rate <80 ml/min/1.73 m(2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Endocrine complications (hypogonadism and delayed growth)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Femoral tunnel widening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: stress incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean height of ejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage below the EDH of the mean ejection height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of descent at the point of ejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADP-stimulated platelet activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Primary hemostasis inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Platelet microparticle formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incremental plantar flexion exercise tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phosphocreatine depletion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of phosphocreatine resynthesis after exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of hemorrhagic stroke
Endpoint domain: Mortality/survival
Primary endpoint: Change in SF‐36 physical component summary scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Risk factors for sudden cardiac death
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of spinal segments with hypesthesia to cold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of spinal segments with hypesthesia for pinprick
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Standing systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Standing diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incremental cost-effectiveness ratio (ICER) per gained quality-adjusted life year (QALY)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Survival rates of CD3+, CD4+, and CD4+/CD8+ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postoperative chest tube blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Postoperative lactate concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to discontinue walker use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to discontinue all gait aids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean steps per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early dyspnea improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in general wellbeing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: IGF‐I standard deviation scores (SDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Body composition and cardiovascular risk markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Glucose tolerance levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: paO2 levels during OLV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: alveolar-arterial oxygen gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Contraceptive choice
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Angiographic progression (change in minimal diameter)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Coronary heart disease events
Endpoint domain: Mortality/survival
Primary endpoint: Peak serum drug concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum half-life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: posttreatment vocational activity
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: posttreatment educational engagement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: V30 for lungs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: V30 for heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total wake time (TWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Sleep efficiency (SE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Non-rapid eye movement (REM) sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Bacteriological recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Acquired rifamycin resistance (ARR)
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of serious infections
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in dietary fat and fiber behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intentions to change fat and fiber intake
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: rate of target vessel failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: frequency of need for revascularization of the target lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: frequency of neointimal hyperplasia within the stent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percent recovery of maximum resting pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent recovery of maximum squeeze pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in TNSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High-density lipoprotein cholesterol increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tolerability of dalcetrapib
Endpoint domain: Adverse events/effects
Primary endpoint: Median number of TGF-alpha-containing cells in the mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bleeding on probing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in parental information, motivation, and behavioral skills regarding fever management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average number of falls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average number of drugs prescribed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Average drug costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 6-minute walking distance (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma BNP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative secretion of proinflammatory cytokines IL-1beta and IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postoperative secretion of anti-inflammatory cytokine IL-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decrease in PAI-1 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Increase in t-PA activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Systolic BP/diastolic BP mean reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Oocyte retrieval rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of follicles > 14 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Cycle abandonment rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Preventive knowledge scores on HIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention behavior scores on HIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inappropriate use of diagnostic tests and treatment of bronchiolitis
Endpoint domain: Adverse events/effects
Primary endpoint: All-cause deaths
Endpoint domain: Mortality/survival
Primary endpoint: White blood cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Platelet function impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in trunk adiposity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: maximum plasma concentration of fexofenadine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oral clearance of fexofenadine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of Tc‐99m tetrofosmin scintimammography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of Tc‐99m tetrofosmin scintimammography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative predictive value of Tc‐99m tetrofosmin scintimammography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of inappropriate antibiotic prescribing for ARTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: esthetic grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: operating time for blepharoplasty
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Visual acuity changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NEI-VFQ scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Myocardial infarction events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stroke events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Progression to AIDS or death
Endpoint domain: Mortality/survival
Primary endpoint: overall patient preparedness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in HbA1c from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean reduction of excess arm volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute volume loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity for prediction of adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy for prediction of adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery within 24 months
Endpoint domain: Mortality/survival
Primary endpoint: Development of new mood episodes
Endpoint domain: Adverse events/effects
Primary endpoint: POBF (Pulsatile Ocular Blood Flow)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: headache freedom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: favorable outcomes at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: very favorable outcomes at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serious intracranial bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: Total perioperative blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Activity improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Global impression of recovery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: threshold shifts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of daily bowel movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Urgency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incontinence grading and scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Left ventricular cleft occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient global assessment of disease activity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient assessment of pain
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Functional Assessment of Chronic Illness Therapy-Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Subjective success rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Objective cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Re-operation rate for stress urinary incontinence
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of septicemia
Endpoint domain: Adverse events/effects
Primary endpoint: First week phosphate nadir
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 3-month weight-loss
Endpoint domain: Mortality/survival
Primary endpoint: Urinary excretion of bone collagen resorption markers (PYD and DPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Joint damage scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedural success rate without major complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: In-hospital clinical success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major and minor procedural complications
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom from AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time for sensorial block to reach level T10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total hip BMD change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes